Literature DB >> 11682294

The role of MRI in the intestinal complications in cystic fibrosis.

M Almberger1, E Iannicelli, M Antonelli, M Matrunola, G Cimino, R Passariello.   

Abstract

Fibrosing colonopathy is a complication recently detected in children with cystic fibrosis (CF), and is thought to be associated with the use of high-strength pancreatic enzymes. The goal of this study was to evaluate the effectiveness of magnetic resonance (MR) in detecting possible pathologic gut findings in patients with CF under pancreatic enzyme treatment. Twenty-five patients with CF and pancreatic insufficiency, all under treatment with high-dose pancreatic enzymes, were studied by MR. MR was performed on a 1.5-T magnet by T1-weighted, 2D-FLASH fat-suppression, breath-hold sequences before and after intravenous administration of gadolinium, and by T2-weighted Turbo Spin-Echo (TSE) and Half-Fourier Acquisition Single-Shot Turbo Spin Echo (HASTE) fat-suppression, breath-hold sequences. A superparamagnetic negative oral contrast agent was given 1.5 h before the examination. MR showed a wall thickening of the terminal ileum and the ascending colon (>4-12 mm) in 22 patients; nine of them (wall thickness >4-6 mm) showed both a moderate hyperintensity of the bowel wall on T2-weighted sequences and an enhancement after intravenous gadolinium on T1-weighted sequences; 13 patients (wall thickness >6-12 mm) showed both a great wall enhancement after intravenous gadolinium and an increased signal intensity of the bowel wall on T2-weighted sequences. Fecal impaction without bowel wall involvement was detected in three patients. MR proved to be a useful, noninvasive, diagnostic tool for the evaluation of patients with CF and fibrosing colonopathy. The signal hyperintensity on T2-weighted sequences and the great wall enhancement after intravenous gadolinium administration indicating an acute edematous condition, provide the clinicians useful information for the therapeutic adjustment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11682294     DOI: 10.1016/s0899-7071(01)00326-6

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  2 in total

Review 1.  [MRI in mucoviscidosis (cystic fibrosis)].

Authors:  M Eichinger; M Puderbach; C-P Heussel; H-U Kauczor
Journal:  Radiologe       Date:  2006-04       Impact factor: 0.635

Review 2.  Beyond pancreatic insufficiency and liver disease in cystic fibrosis.

Authors:  Stephanie Demeyer; Kris De Boeck; Peter Witters; Katrien Cosaert
Journal:  Eur J Pediatr       Date:  2016-04-07       Impact factor: 3.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.